Literature Review

Neurofilaments: A Biomarker of Long-Term Outcome in MS?

In patients with multiple sclerosis (MS), levels of light-chain neurofilament (NfL) in CSF at diagnosis seem to predict...

An estimated 3% of patients with multiple sclerosis (MS) have a benign course of disease, according to findings from a...

The prodrome of multiple sclerosis (MS) may include an increased risk of nervous system, sensory, and musculoskeletal disorders, according to...

Deep gray matter volume loss drives disability accumulation in multiple sclerosis (MS), according to a multicenter, longitudinal study published...

Patients with multiple sclerosis (MS) who are treated with natalizumab can have small progressive multifocal leukoencephalopathy (PML) lesions on...

Among patients with secondary progressive multiple sclerosis (MS), siponimod appears to decrease the risk of disability progression, according to...

Women with relapsing-remitting multiple sclerosis (MS) who discontinue natalizumab treatment before pregnancy may have increased disease activity...

Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published a...

The 2016 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) criteria have accuracy similar to that of the 2010 McDonald criteria in...